Aurobindo Pharma is currently trading at Rs 194.50, up by 0.70 points or 0.36% from its previous closing of Rs 193.80 on the BSE.
The scrip opened at Rs 198.40 and has touched a high and low of Rs 198.50 and Rs 192.75 respectively. So far 235783 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 1 has touched a 52 week high of Rs 275.00 on 05-Jan-2011 and a 52 week low of Rs 156.50 on 25-Feb-2011.
Last one week high and low of the scrip stood at Rs 203.95 and Rs 184.65 respectively. The current market cap of the company is Rs 5649.21 crore.
The promoters holding in the company stood at 54.40% while Institutions and Non-Institutions held 35.80% and 9.81% respectively. Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Fosinopril Sodium Tablets USP 10mg, 20mg and 40mg.
Fosinopril Sodium Tablets USP 10mg, 20mg, and 40mg is the generic version of Bristol-Myers Squibb Company Pharmaceutical Research Institute’s Monopril tablets 10mg, 20mg, and 40mg. The product falls under the cardiovascular (CVS) therapeutic category and is indicated for the treatment of hypertension. The product has a market size of about $20 million for the twelve months ending September 2010.
No comments:
Post a Comment